Company Announcement no. 22/2012
To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 14 November 2012
Veloxis Pharmaceuticals A/S establishes a new Warrant Programme for the Employees of the Company
Today, the Board of Directors of Veloxis Pharmaceuticals A/S (the "Company") has decided to establish a new warrant programme for the employees of the Company. Thus, the Board of Directors of the Company has today partly exercised its authorisation pursuant to Section 5A of the Articles of Association.
Warrants are awarded to all employees.
The purpose of the grant of warrants is to reflect the Company's objective to attract and retain first-rate employees and thus ensure a long-term shareholder value creation. The grant of warrants shall ensure to create - both in the short and in the long run - common interests between the employees and the shareholders of the Company.
A total of 59,047,200 warrants are to be awarded, giving the right to subscription of up to 59,047,200 shares each of DKK 0.1. The exercise price is fixed at DKK 0.35.
The warrant holders earn the right to exercise warrants with 1/36 per month as from the date of grant 14 November 2012.
After having earned the right to exercise a warrant, the warrant holder may exercise the warrant in the exercise periods, see below.
The exercise periods run for 21 days, respectively as from the day following i) the Company's publication of the announcement of the annual report or - if such announcement is not published - of the annual report, and ii) the Company's publication of the interim report and iii) the interim financial report for the first 3 months and the Company's publication of its financial report for the first 9 months of the year. Warrants that are not exercised on 14 November 2019 expire automatically.
It is a condition for exercise of the granted warrants that the warrant holders waive their rights to exercise existing warrants. This means that up to 17,922,234 number of warrants cannot be exercised.
The issued warrants are estimated to have a total market value of approx. DKK 8,857,080. The market value of the issued warrants is calculated on basis of the Black-Scholes model with a volatility calculated as 0.53, an interest level of 0.49 per cent, and a share price of DKK 0.35.
For more information, please contact:
Veloxis Pharmaceuticals A/S
Bill Polvino Johnny Stilou
President & CEO EVP, Chief Financial Officer
Mobile: +1 917 647 9107 Mobile: +45 21 227 227
Email: firstname.lastname@example.org Email: email@example.com
For further information, please visit www.veloxis.com
About Veloxis Pharmaceuticals
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is LCP-Tacro for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.